This application is a renewal of an RO1 to understand the mechanisms by which EGF receptor family members are activated and signal. The family of receptors includes the EGF receptor itself, Neu, ErbB3 and ErbB4. It is noted in the application that ligand binding to a particular receptor induces or stabilizes homo- or heterodimer formation. The properties of the latter are especially interesting but not particularly well known. The initial emphasis of the proposal is on complexes established between the ErbB3 and Neu and the EGF receptor and Neu.
The first aim deals with mechanisms of activation, and specifically how ErbB3, which is not an effective tyrosine kinase, promotes activation of Neu upon binding heregulin, and whether Neu is activated at all by the EGF receptor. The answers to both will be achieved by reconstitution of purified normal or mutant proteins in phospholipid vesicles.
The second aim addresses proximal signaling molecules. One hypothesis is that tyrosine phosphorylation of ErbB3 by Neu accounts for binding of ErbB3 to p85. Also to be examined is the mechanism by which the EGF receptor achieves phosphorylation of the Cbl protooncogene.
The third aim i s to understand better pathways employed by the EGF receptor family further downstream. The potential for activation of the stress-activated MAP kinases will be examined, since some evidence exists for Cdc42 activation, and the identity of a novel GTP-binding protein activated by EGF and heregulin will also be explored. The GTP-binding protein is nuclear, binds RCC1, and is activated by UV light as well as growth factors.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM040654-10
Application #
2022247
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Project Start
1988-07-01
Project End
2001-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Cornell University
Department
Pharmacology
Type
Schools of Veterinary Medicine
DUNS #
City
Ithaca
State
NY
Country
United States
Zip Code
14850
Cerione, Richard A (2018) The experiences of a biochemist in the evolving world of G protein-dependent signaling. Cell Signal 41:2-8
Huang, Qingqiu; Stalnecker, Clint; Zhang, Chengliang et al. (2018) Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem 293:3535-3545
Antonyak, Marc A; Cerione, Richard A (2018) The distinct traits of extracellular vesicles generated by transformed cells. Small GTPases 9:427-432
Lukey, Michael J; Katt, William P; Cerione, Richard A (2017) Targeting amino acid metabolism for cancer therapy. Drug Discov Today 22:796-804
Yoo, Sungsoo M; Latifkar, Arash; Cerione, Richard A et al. (2017) Cool-associated Tyrosine-phosphorylated Protein 1 Is Required for the Anchorage-independent Growth of Cervical Carcinoma Cells by Binding Paxillin and Promoting AKT Activation. J Biol Chem 292:3947-3957
Cluntun, Ahmad A; Lukey, Michael J; Cerione, Richard A et al. (2017) Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer 3:169-180
Yoo, Sungsoo M; Cerione, Richard A; Antonyak, Marc A (2017) The Arf-GAP and protein scaffold Cat1/Git1 as a multifaceted regulator of cancer progression. Small GTPases :1-9
Feng, Qiyu; Zhang, Chengliang; Lum, David et al. (2017) A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun 8:14450
Stalnecker, Clint A; Erickson, Jon W; Cerione, Richard A (2017) Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. J Biol Chem 292:6095-6107
Katt, William P; Lukey, Michael J; Cerione, Richard A (2017) A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. Future Med Chem 9:223-243

Showing the most recent 10 out of 84 publications